Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis
NCT: NCT02575625 · COMPLETED
Brief Summary
Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition. This proof of concept validation is made up of two steps: * Step 1: feasibility study of the method on 10 healthy volunteers * Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an liver biopsy et whom the histological answer is clean steatosis (NAFLD). Experimental procedures consist in: * Fibroscan measure, preceded by tracking ultrasonography. * liver MRI (for substudy about MRI comparison, in step 2) * a blood test for biological assessment of liver functions
Frequently Asked Questions
What is Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis?
Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis is a clinical trial registered under NCT02575625. Current status: COMPLETED.
What is the status of NCT02575625?
The current status of NCT02575625 (Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis) is: COMPLETED.
When did Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis start?
Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis started on 2013-04.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.